Tissue Repair Ltd
Tissue Repair Ltd (TRP.AX) Financial Performance & Income Statement Overview
Review Tissue Repair Ltd (TRP.AX) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Tissue Repair Ltd (TRP.AX) Income Statement & Financial Overview
View the income breakdown for Tissue Repair Ltd TRP.AX across both annual and quarterly reports.
| Metric | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 |
|---|---|---|---|---|
| Revenue | $654319.00 | $1.73M | $58586.00 | $3076.00 |
| Cost of Revenue | $0.00 | $5218.00 | $916952.00 | $1530.00 |
| Gross Profit | $654319.00 | $1.73M | -$858366.00 | $1546.00 |
| Gross Profit Ratio | $1.00 | $1.00 | -$14.65 | $0.50 |
| R&D Expenses | $1.76M | $2.25M | $987101.00 | $840682.00 |
| SG&A Expenses | $2.09M | $1.83M | $688139.00 | $1.52M |
| Operating Expenses | $3.84M | $4.08M | $1.68M | $2.36M |
| Total Costs & Expenses | $3.84M | $4.09M | $2.59M | $2.36M |
| Interest Income | $0.00 | $695052.00 | $395850.00 | $315979.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $2583.00 | $1830.00 | $814.00 | $1530.00 |
| EBITDA | -$3.19M | -$2.34M | -$2.26M | -$1.99M |
| EBITDA Ratio | -$4.88 | -$1.35 | -$38.51 | -$765.54 |
| Operating Income | -$3.19M | -$2.35M | -$2.53M | -$2.36M |
| Operating Income Ratio | -$4.88 | -$1.36 | -$43.25 | -$766.04 |
| Other Income/Expenses (Net) | $629171.00 | -$1.17M | $276597.00 | $367529.00 |
| Income Before Tax | -$2.56M | -$3.52M | -$2.26M | -$1.99M |
| Income Before Tax Ratio | -$3.91 | -$2.03 | -$38.52 | -$646.55 |
| Income Tax Expense | $0.00 | -$1.64M | -$4.00 | -$968579.00 |
| Net Income | -$2.56M | -$1.88M | -$2.26M | -$1.02M |
| Net Income Ratio | -$3.91 | -$1.09 | -$38.52 | -$331.67 |
| EPS | -$0.04 | -$0.03 | -$0.04 | -$0.02 |
| Diluted EPS | -$0.04 | -$0.03 | -$0.04 | -$0.02 |
| Weighted Avg Shares Outstanding | $60.40M | $60.46M | $60.46M | $60.46M |
| Weighted Avg Shares Outstanding (Diluted) | $60.40M | $60.46M | $60.46M | $60.46M |
The company's financials show resilient growth, with revenue advancing from $3076.00 in Q4 2023 to $654319.00 in Q2 2025. Gross profit remained healthy with margins at 100% in Q2 2025 compared to 50% in Q4 2023. Operating income hit -$3.19M last quarter, sustaining a consistent -488% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$3.19M. Net income dropped to -$2.56M, while earnings per share reached -$0.04. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan